SOAT1 and diabetic kidney disease: The JAK-STAT inhibitors have been used in the treatment of various immune-mediated diseases including psoriasis, spondyloarthritis, rheumatoid arthritis, and inflammatory bowel disease [177], supporting their potential therapeutic role in slowing the progression of DKD.